The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Clifford Chance has handled its first no-win no-fee case
The firm was acting for the Multiple Sclerosis Society in its successful campaign to persuade the Government to dispense the controversial MS drug Beta Interferon on the NHS. Clifford Chance took the case on a pro bono basis, but agreed that the CFA could be a productive tactic. This way, the MS Society would not have to pay Clifford Chance if it lost the case, but if it won, the Government would have to pay the costs, estimated at no less than £250,000. The firm worked on the case for two years. However, it did not have the chance to implement the CFA in court. The firm was planning to take it to the High Court when the Government changed its policy and ordered the NHS to pay for the drug.